In this episode, Ushma Neill interviews the physician scientist and gene therapy, pioneer Dr. Katherine High. After a long career as an academic hematologist, first at the University of North Carolina, then at the University of Pennsylvania and HHMI, Kathy transitioned to a role in industry, first at Spark Therapeutics, then at ASK Biopharma where she led the first FDA approval for gene therapy for a genetic disease.
Neonatologist and pulmonary biologist Jeffrey Whitsett of the Cincinnati Children’s Hospital provided understanding of pulmonary surfactant biochemistry and structural biology that underpins the widespread application and usage of surfactant replacement therapy in neonatal respiratory distress.
In this episode, Lasse Giil explains that activation of the kynurenine pathway in delirium leads to high brain concentrations the endogenous neurotoxin quinolinic acid.
In this episode, Nima Sharifi and Xiuxiu Li discuss how the BMX kinase regulates androgen and estrogen biosynthesis and is a drug target for sex steroid dependent cancers.
Lo is often called the father of noninvasive prenatal testing. After discovering fetal DNA in maternal blood, Lo catalyzed a medical revolution that has saved millions of pregnant people from having to undergo invasive tests like amniocentesis. With Lo’s pioneering technical advances, those who are pregnant can easily and reliably be screened for Rh factor mismatch, trisomies, and genetic disorders, and the implications of his work have and may go further in cancer testing, transplantation, and perhaps beyond.